1
|
Lin Y, Yilmaz EC, Belue MJ, Harmon SA, Tetreault J, Phelps TE, Merriman KM, Hazen L, Garcia C, Yang D, Xu Z, Lay NS, Toubaji A, Merino MJ, Xu D, Law YM, Gurram S, Wood BJ, Choyke PL, Pinto PA, Turkbey B. Evaluation of a Cascaded Deep Learning-based Algorithm for Prostate Lesion Detection at Biparametric MRI. Radiology 2024; 311:e230750. [PMID: 38713024 DOI: 10.1148/radiol.230750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2024]
Abstract
Background Multiparametric MRI (mpMRI) improves prostate cancer (PCa) detection compared with systematic biopsy, but its interpretation is prone to interreader variation, which results in performance inconsistency. Artificial intelligence (AI) models can assist in mpMRI interpretation, but large training data sets and extensive model testing are required. Purpose To evaluate a biparametric MRI AI algorithm for intraprostatic lesion detection and segmentation and to compare its performance with radiologist readings and biopsy results. Materials and Methods This secondary analysis of a prospective registry included consecutive patients with suspected or known PCa who underwent mpMRI, US-guided systematic biopsy, or combined systematic and MRI/US fusion-guided biopsy between April 2019 and September 2022. All lesions were prospectively evaluated using Prostate Imaging Reporting and Data System version 2.1. The lesion- and participant-level performance of a previously developed cascaded deep learning algorithm was compared with histopathologic outcomes and radiologist readings using sensitivity, positive predictive value (PPV), and Dice similarity coefficient (DSC). Results A total of 658 male participants (median age, 67 years [IQR, 61-71 years]) with 1029 MRI-visible lesions were included. At histopathologic analysis, 45% (294 of 658) of participants had lesions of International Society of Urological Pathology (ISUP) grade group (GG) 2 or higher. The algorithm identified 96% (282 of 294; 95% CI: 94%, 98%) of all participants with clinically significant PCa, whereas the radiologist identified 98% (287 of 294; 95% CI: 96%, 99%; P = .23). The algorithm identified 84% (103 of 122), 96% (152 of 159), 96% (47 of 49), 95% (38 of 40), and 98% (45 of 46) of participants with ISUP GG 1, 2, 3, 4, and 5 lesions, respectively. In the lesion-level analysis using radiologist ground truth, the detection sensitivity was 55% (569 of 1029; 95% CI: 52%, 58%), and the PPV was 57% (535 of 934; 95% CI: 54%, 61%). The mean number of false-positive lesions per participant was 0.61 (range, 0-3). The lesion segmentation DSC was 0.29. Conclusion The AI algorithm detected cancer-suspicious lesions on biparametric MRI scans with a performance comparable to that of an experienced radiologist. Moreover, the algorithm reliably predicted clinically significant lesions at histopathologic examination. ClinicalTrials.gov Identifier: NCT03354416 © RSNA, 2024 Supplemental material is available for this article.
Collapse
Affiliation(s)
- Yue Lin
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Enis C Yilmaz
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Mason J Belue
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Stephanie A Harmon
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Jesse Tetreault
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Tim E Phelps
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Katie M Merriman
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Lindsey Hazen
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Charisse Garcia
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Dong Yang
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Ziyue Xu
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Nathan S Lay
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Antoun Toubaji
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Maria J Merino
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Daguang Xu
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Yan Mee Law
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Sandeep Gurram
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Bradford J Wood
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Peter L Choyke
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Peter A Pinto
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| | - Baris Turkbey
- From the Molecular Imaging Branch (Y.L., E.C.Y., M.J.B., S.A.H., T.E.P., K.M.M., N.S.L., P.L.C., B.T.), Center for Interventional Oncology (L.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; NVIDIA, Santa Clara, Calif (J.T., D.Y., Z.X., D.X.); Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md (L.H., C.G., B.J.W.); and Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.)
| |
Collapse
|
2
|
Faure A, Paye Jaouen A, Demede D, Juricic M, Arnaud A, Garcia C, Charbonnier M, Abbo O, Botto N, Blanc T, Leclair MD, Loubersac T. Safety and feasability of ureteroscopy for pediatric stone, in children under 5 Years (SFUPA 5): A French multicentric study. J Pediatr Urol 2024; 20:225.e1-225.e8. [PMID: 38030430 DOI: 10.1016/j.jpurol.2023.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 11/09/2023] [Accepted: 11/15/2023] [Indexed: 12/01/2023]
Abstract
INTRODUCTION Ureteroscopy (URS) can be proposed as first-line therapy for the management of pelvic stones from 10 to 20 mm and for lower ureteric stones in children. However, little is known about the success and the morbidity of URS in young children. Ureteroscopic treatment may present matters in young children because of the small size of the pediatric kidney and the small size of the collecting system. OBJECTIVE To assess safety and efficacy of URS for the treatment of urinary stones in children aged of 5 years or less. STUDY DESIGN After the institutional ethical board approval was obtained, we conducted a retrospective, analytic, multicentric study that included all URS performed between January 2016 and April 2022 in children aged of 5 years or less. In this non-comparative case series, anonymized pooled data were collected from 7 tertiary care centers of pediatric patients. Endpoints were the one-session SFR at 3 months and per and postoperatives complications. Descriptive statistics were applied to describe the cohort. RESULTS Eighty-three patients were included. For them, 96 procedures were performed at the median age of 3.5 years (IQR: 0.8-5) and median weight of 14 Kg (6.3-23). Median stone size was 13 mm (4-45). There were 65 (67 %) renal stones treated with flexible URS, most of which were in the renal pelvis (30 %) and in the lower calix (33 %). A ureteral access sheath was used in 91 % procedures. Preoperative ureteral stent was placed in 52 (54 %) of patients. None of patients had ureteral dilatation. The single-session SFR was 67.4 % (56.3 and 89.2 % for flexible URS and semi-rigid URS respectively) and children require 1.4 procedures to achieve complete stone clearance. The overall complication rate was 18.7 %, most of them were minor (Clavien I-II). Intraoperative perirenal extravasation (Clavien IIIb) due to forniceal rupture was documented in 6.2 % of cases, related to an increased intrapelvic pressure (IPP) performed in a closed pelvicalyceal system. DISCUSSION Pediatric urologists should be aware of forniceal rupture based on the presence of extravasation of contrast during endourological procedures especially when they have difficulties to reach lower caliceal stone in small patient. CONCLUSION URS in patients aged of 5 years or less, is a complex minimally invasive procedure with reasonable efficacy and low morbidity. Intrarenal stones treated by RIRS in young children carries the risk of additional procedures to complete stone clearance.
Collapse
Affiliation(s)
- A Faure
- APHM, Aix Marseille University, Timone Enfants, Department of Pediatric Surgery, Marseille, France.
| | - A Paye Jaouen
- APHP, Robert-Debré University Hospital, National Reference Center for Rare Urinary Tract Diseases "MARVU", Pediatric Urology, Paris, France
| | - D Demede
- University Hospital of Lyon, Pediatric Urology, Lyon, France
| | - M Juricic
- University Hospital of Rennes, Pediatric Urology, Rennes, France
| | - A Arnaud
- University Hospital of Rennes, Pediatric Urology, Rennes, France
| | - C Garcia
- University Hospital of Toulouse, Pediatric Urology, Toulouse, France
| | - M Charbonnier
- APHM, Aix Marseille University, Timone Enfants, Department of Pediatric Surgery, Marseille, France
| | - O Abbo
- University Hospital of Toulouse, Pediatric Urology, Toulouse, France
| | - N Botto
- Department of Pediatric Surgery and Urology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - T Blanc
- Department of Pediatric Surgery and Urology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France
| | - M D Leclair
- Nantes Université, Pediatric Urology, Nantes, France
| | - T Loubersac
- Nantes Université, Pediatric Urology, Nantes, France
| |
Collapse
|
3
|
Garcia-Llorens J, Garcia C, Paulet P, Le-Tallec B, Dauphin G, Comte S, Catalá-Gregori P, Simon F, Sevilla-Navarro S, Sarabia J. Research Note: Validation of a new differentiation approach using the commercial ASAP TM media to detect the Salmonella 441/014 vaccine strain. Poult Sci 2024; 103:103679. [PMID: 38701627 DOI: 10.1016/j.psj.2024.103679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 03/14/2024] [Accepted: 03/16/2024] [Indexed: 05/05/2024] Open
Abstract
Vaccination is one of the most important control tools to reduce Salmonella in poultry production. In order for a live vaccine to be licensed for field use it should be provided with the detection methods to differentiate it from field strains. This paper aims to describe the validation of an alternative method for the differentiation of the Salmonella 441/014 vaccine strain from field strains, using a chromogenic Media, ASAP from bioMérieux. The ASAP-based differentiation method was compared with already authorized methods, namely the Anicon SE Kylt PCR DIVA 1 assay and Ceva S-Check Salmonella differentiation kit, following the ISO 16140-6:2019 validation method guidelines. A Generalised Linear Model was fitted to the data to determine the inclusivity and exclusivity of differentiation methods (PCR Kylt vs. S-Check vs. ASAPTM). Statistical differences were based on a P-value level of < 0.05 (SPSS Inc., Chicago, IL). In this study, we show that the ASAP media was able to differentiate Salmonella Enteritidis vaccine strains from field strains, obtaining 100% agreement between the three differentiation assays. This differentiation approach is quicker, easier to deploy and cheaper as compared to alternative methods.
Collapse
Affiliation(s)
- J Garcia-Llorens
- Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (CECAV), 12539, Alquerías del Niño Perdido, Castellón, Spain
| | - C Garcia
- Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (CECAV), 12539, Alquerías del Niño Perdido, Castellón, Spain
| | - P Paulet
- Ceva Santé Animale, 10 Avenue de la Ballastière, 33500 Libourne, France
| | - B Le-Tallec
- Ceva Santé Animale, 10 Avenue de la Ballastière, 33500 Libourne, France
| | - G Dauphin
- Ceva Santé Animale, 10 Avenue de la Ballastière, 33500 Libourne, France
| | - S Comte
- Ceva Santé Animale, 10 Avenue de la Ballastière, 33500 Libourne, France
| | - P Catalá-Gregori
- Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (CECAV), 12539, Alquerías del Niño Perdido, Castellón, Spain
| | - F Simon
- bioMérieux, Marcy l'Etoile, 69280, France
| | - S Sevilla-Navarro
- Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (CECAV), 12539, Alquerías del Niño Perdido, Castellón, Spain.
| | - J Sarabia
- Ceva Santé Animale, 10 Avenue de la Ballastière, 33500 Libourne, France
| |
Collapse
|
4
|
Yilmaz EC, Lin Y, Belue MJ, Harmon SA, Phelps TE, Merriman KM, Hazen LA, Garcia C, Johnson L, Lay NS, Toubaji A, Merino MJ, Patel KR, Parnes HL, Law YM, Wood BJ, Gurram S, Choyke PL, Pinto PA, Turkbey B. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy. AJR Am J Roentgenol 2024; 222:e2329964. [PMID: 37729551 DOI: 10.2214/ajr.23.29964] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
BACKGROUND. Precise risk stratification through MRI/ultrasound (US) fusion-guided targeted biopsy (TBx) can guide optimal prostate cancer (PCa) management. OBJECTIVE. The purpose of this study was to compare PI-RADS version 2.0 (v2.0) and PI-RADS version 2.1 (v2.1) in terms of the rates of International Society of Urological Pathology (ISUP) grade group (GG) upgrade and downgrade from TBx to radical prostatectomy (RP). METHODS. This study entailed a retrospective post hoc analysis of patients who underwent 3-T prostate MRI at a single institution from May 2015 to March 2023 as part of three prospective clinical trials. Trial participants who underwent MRI followed by MRI/US fusion-guided TBx and RP within a 1-year interval were identified. A single genitourinary radiologist performed clinical interpretations of the MRI examinations using PI-RADS v2.0 from May 2015 to March 2019 and PI-RADS v2.1 from April 2019 to March 2023. Upgrade and downgrade rates from TBx to RP were compared using chi-square tests. Clinically significant cancer was defined as ISUP GG2 or greater. RESULTS. The final analysis included 308 patients (median age, 65 years; median PSA density, 0.16 ng/mL2). The v2.0 group (n = 177) and v2.1 group (n = 131) showed no significant difference in terms of upgrade rate (29% vs 22%, respectively; p = .15), downgrade rate (19% vs 21%, p = .76), clinically significant upgrade rate (14% vs 10%, p = .27), or clinically significant downgrade rate (1% vs 1%, p > .99). The upgrade rate and downgrade rate were also not significantly different between the v2.0 and v2.1 groups when stratifying by index lesion PI-RADS category or index lesion zone, as well as when assessed only in patients without a prior PCa diagnosis (all p > .01). Among patients with GG2 or GG3 at RP (n = 121 for v2.0; n = 103 for v2.1), the concordance rate between TBx and RP was not significantly different between the v2.0 and v2.1 groups (53% vs 57%, p = .51). CONCLUSION. Upgrade and downgrade rates from TBx to RP were not significantly different between patients whose MRI examinations were clinically interpreted using v2.0 or v2.1. CLINICAL IMPACT. Implementation of the most recent PI-RADS update did not improve the incongruence in PCa grade assessment between TBx and surgery.
Collapse
Affiliation(s)
- Enis C Yilmaz
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Yue Lin
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Mason J Belue
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Stephanie A Harmon
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Tim E Phelps
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Katie M Merriman
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Lindsey A Hazen
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD
- Department of Radiology, Clinical Center, NIH, Bethesda, MD
| | - Charisse Garcia
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD
- Department of Radiology, Clinical Center, NIH, Bethesda, MD
| | - Latrice Johnson
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Nathan S Lay
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Antoun Toubaji
- Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD
| | - Krishnan R Patel
- Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD
| | - Howard L Parnes
- Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD
| | - Yan Mee Law
- Department of Radiology, Singapore General Hospital, Singapore
| | - Bradford J Wood
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD
- Department of Radiology, Clinical Center, NIH, Bethesda, MD
| | - Sandeep Gurram
- Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD
| | - Peter L Choyke
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| | - Peter A Pinto
- Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD
| | - Baris Turkbey
- Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892
| |
Collapse
|
5
|
Enders JJ, Pinto PA, Xu S, Gomella P, Rothberg MB, Noun J, Blake Z, Daneshvar M, Seifabadi R, Nemirovsky D, Hazen L, Garcia C, Li M, Gurram S, Choyke PL, Merino MJ, Toubaji A, Turkbey B, Varble N, Wood BJ. A Novel Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy Technique Using Transperineal Ultrasound: An Initial Experience. Urology 2023; 181:76-83. [PMID: 37572884 DOI: 10.1016/j.urology.2023.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 06/02/2023] [Accepted: 06/12/2023] [Indexed: 08/14/2023]
Abstract
OBJECTIVE To report an initial experience with a novel, "fully" transperineal (TP) prostate fusion biopsy using an unconstrained ultrasound transducer placed on the perineal skin to guide biopsy needles inserted via a TP approach. METHODS Conventional TP prostate biopsies for detection of prostate cancer have been performed with transrectal ultrasound, requiring specialized hardware, imposing limitations on needle trajectory, and contributing to patient discomfort. Seventy-six patients with known or suspected prostate cancer underwent 78 TP biopsy sessions in an academic center between June 2018 and April 2022 and were included in this study. These patients underwent TP prostate fusion biopsy using a grid or freehand device with transrectal ultrasound as well as TP prostate fusion biopsy using TP ultrasound in the same session. Per-session and per-lesion cancer detection rates were compared for conventional and fully TP biopsies using Fisher exact and McNemar's tests. RESULTS After a refinement period in 30 patients, 92 MRI-visible prostate lesions were sampled in 46 subsequent patients, along with repeat biopsies in 2 of the 30 patients from the refinement period. Grade group ≥2 cancer was diagnosed in 24/92 lesions (26%) on conventional TP biopsy (17 lesions with grid, 7 with freehand device), and in 25/92 lesions (27%) on fully TP biopsy (P = 1.00), with a 73/92 (79%) rate of agreement for grade group ≥2 cancer between the two methods. CONCLUSION Fully TP biopsy is feasible and may detect prostate cancer with detection rates comparable to conventional TP biopsy.
Collapse
Affiliation(s)
- Jacob J Enders
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD; Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Peter A Pinto
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Sheng Xu
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Patrick Gomella
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Michael B Rothberg
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Jibriel Noun
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Zoe Blake
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Michael Daneshvar
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Reza Seifabadi
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Daniel Nemirovsky
- Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD
| | - Lindsey Hazen
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Charisse Garcia
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Ming Li
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Sandeep Gurram
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD
| | - Peter L Choyke
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Antoun Toubaji
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Baris Turkbey
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Nicole Varble
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD; Philips Research North America, Cambridge, MA
| | - Bradford J Wood
- Center for Interventional Oncology, National Institutes of Health, Bethesda, MD; Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD; National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD.
| |
Collapse
|
6
|
Yilmaz EC, Harmon SA, Belue MJ, Merriman KM, Phelps TE, Lin Y, Garcia C, Hazen L, Patel KR, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Citrin DE, Turkbey B. Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI. Eur J Radiol 2023; 168:111095. [PMID: 37717420 PMCID: PMC10615746 DOI: 10.1016/j.ejrad.2023.111095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 09/04/2023] [Accepted: 09/12/2023] [Indexed: 09/19/2023]
Abstract
OBJECTIVE To evaluate a biparametric MRI (bpMRI)-based artificial intelligence (AI) model for the detection of local prostate cancer (PCa) recurrence in patients with radiotherapy history. MATERIALS AND METHODS This study included post-radiotherapy patients undergoing multiparametric MRI and subsequent MRI/US fusion-guided and/or systematic biopsy. Histopathology results were used as ground truth. The recurrent cancer detection sensitivity of a bpMRI-based AI model, which was developed on a large dataset to primarily identify lesions in treatment-naïve patients, was compared to a prospective radiologist assessment using the Wald test. Subanalysis was conducted on patients stratified by the treatment modality (external beam radiation treatment [EBRT] and brachytherapy) and the prostate volume quartiles. RESULTS Of the 62 patients included (median age = 70 years; median PSA = 3.51 ng/ml; median prostate volume = 27.55 ml), 56 recurrent PCa foci were identified within 46 patients. The AI model detected 40 lesions in 35 patients. The AI model performance was lower than the prospective radiology interpretation (Rad) on a patient-(AI: 76.1% vs. Rad: 91.3%, p = 0.02) and lesion-level (AI: 71.4% vs. Rad: 87.5%, p = 0.01). The mean number of false positives per patient was 0.35 (range: 0-2). The AI model performance was higher in EBRT group both on patient-level (EBRT: 81.5% [22/27] vs. brachytherapy: 68.4% [13/19]) and lesion-level (EBRT: 79.4% [27/34] vs. brachytherapy: 59.1% [13/22]). In patients with gland volumes >34 ml (n = 25), detection sensitivities were 100% (11/11) and 94.1% (16/17) on patient- and lesion-level, respectively. CONCLUSION The reported bpMRI-based AI model detected the majority of locally recurrent prostate cancer after radiotherapy. Further testing including external validation of this model is warranted prior to clinical implementation.
Collapse
Affiliation(s)
- Enis C Yilmaz
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Stephanie A Harmon
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Mason J Belue
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Katie M Merriman
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Tim E Phelps
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Yue Lin
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Charisse Garcia
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD, United States
| | - Lindsey Hazen
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD, United States
| | - Krishnan R Patel
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Bradford J Wood
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD, United States
| | - Peter L Choyke
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Peter A Pinto
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Deborah E Citrin
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Baris Turkbey
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, MD, United States.
| |
Collapse
|
7
|
Reguiai Z, Becherel PA, Fougerousse AC, Chaby G, Perrot JL, Begon E, Jacobzone-Lévêque C, Boulard C, Badaoui A, Poreaux C, David L, Quiles-Tsimaratos N, Lons-Danic D, Fite C, Liegeon AL, Patchinsky A, Parier J, Garcia C, Estève E, Mohty R, Mery-Bossard L, Maccari F. Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures. J Eur Acad Dermatol Venereol 2023; 37:e1307-e1309. [PMID: 37415328 DOI: 10.1111/jdv.19302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 06/26/2023] [Indexed: 07/08/2023]
Affiliation(s)
- Z Reguiai
- Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France
| | - P A Becherel
- Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France
| | - A C Fougerousse
- Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France
| | - G Chaby
- Department of Dermatology, CHU Amiens-Picardie, Amiens, France
| | - J L Perrot
- Department of Dermatology, CHU Saint Etienne, Saint Etienne, France
| | - E Begon
- Department of Dermatology, Centre Hospitalier René Dubos, Pontoise, France
| | | | - C Boulard
- Department of Dermatology, Centre Hospitalier Le Havre, Le Havre, France
| | | | - C Poreaux
- Centre de Dermatologie Stanislas, Clinique Pasteur, Nancy, France
| | - L David
- Department of Dermatology, Hopital Saint Joseph, Marseille, France
| | | | - D Lons-Danic
- Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France
| | - C Fite
- Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France
| | - A-L Liegeon
- Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France
| | - A Patchinsky
- Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France
| | - J Parier
- Centre de Santé Sabouraud, Hôpital Saint-Louis, Paris, France
- Cabinet Médical, Saint-Maur-des-Fossés, France
| | - C Garcia
- Department of Dermatology, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France
| | - E Estève
- Department of Dermatology, Centre Hospitalier d'Orléans, Orléans, France
| | - R Mohty
- Cabinet Médical, Beauvais, France
| | - L Mery-Bossard
- Department of Dermatology, CHI Poissy Saint Germain, Saint-Germain-en-Laye, France
| | - F Maccari
- Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France
- Cabinet Médical, Saint-Maur-des-Fossés, France
| |
Collapse
|
8
|
Lin Y, Belue MJ, Yilmaz EC, Harmon SA, An J, Law YM, Hazen L, Garcia C, Merriman KM, Phelps TE, Lay NS, Toubaji A, Merino MJ, Wood BJ, Gurram S, Choyke PL, Pinto PA, Turkbey B. Deep Learning-Based T2-weighted MR Image Quality Assessment and Its Impact on Prostate Cancer Detection Rates. J Magn Reson Imaging 2023:10.1002/jmri.29031. [PMID: 37811666 PMCID: PMC11001787 DOI: 10.1002/jmri.29031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 09/15/2023] [Accepted: 09/15/2023] [Indexed: 10/10/2023] Open
Abstract
BACKGROUND Image quality evaluation of prostate MRI is important for successful implementation of MRI into localized prostate cancer diagnosis. PURPOSE To examine the impact of image quality on prostate cancer detection using an in-house previously developed artificial intelligence (AI) algorithm. STUDY TYPE Retrospective. SUBJECTS 615 consecutive patients (median age 67 [interquartile range [IQR]: 61-71] years) with elevated serum PSA (median PSA 6.6 [IQR: 4.6-9.8] ng/mL) prior to prostate biopsy. FIELD STRENGTH/SEQUENCE 3.0T/T2-weighted turbo-spin-echo MRI, high b-value echo-planar diffusion-weighted imaging, and gradient recalled echo dynamic contrast-enhanced. ASSESSMENTS Scans were prospectively evaluated during clinical readout using PI-RADSv2.1 by one genitourinary radiologist with 17 years of experience. For each patient, T2-weighted images (T2WIs) were classified as high-quality or low-quality based on evaluation of both general distortions (eg, motion, distortion, noise, and aliasing) and perceptual distortions (eg, obscured delineation of prostatic capsule, prostatic zones, and excess rectal gas) by a previously developed in-house AI algorithm. Patients with PI-RADS category 1 underwent 12-core ultrasound-guided systematic biopsy while those with PI-RADS category 2-5 underwent combined systematic and targeted biopsies. Patient-level cancer detection rates (CDRs) were calculated for clinically significant prostate cancer (csPCa, International Society of Urological Pathology Grade Group ≥2) by each biopsy method and compared between high- and low-quality images in each PI-RADS category. STATISTICAL TESTS Fisher's exact test. Bootstrap 95% confidence intervals (CI). A P value <0.05 was considered statistically significant. RESULTS 385 (63%) T2WIs were classified as high-quality and 230 (37%) as low-quality by AI. Targeted biopsy with high-quality T2WIs resulted in significantly higher clinically significant CDR than low-quality images for PI-RADS category 4 lesions (52% [95% CI: 43-61] vs. 32% [95% CI: 22-42]). For combined biopsy, there was no significant difference in patient-level CDRs for PI-RADS 4 between high- and low-quality T2WIs (56% [95% CI: 47-64] vs. 44% [95% CI: 34-55]; P = 0.09). DATA CONCLUSION Higher quality T2WIs were associated with better targeted biopsy clinically significant cancer detection performance for PI-RADS 4 lesions. Combined biopsy might be needed when T2WI is lower quality. LEVEL OF EVIDENCE 2 TECHNICAL EFFICACY: Stage 1.
Collapse
Affiliation(s)
- Yue Lin
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Mason J. Belue
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Enis C. Yilmaz
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Stephanie A. Harmon
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Julie An
- Department of Radiology, University of California San Diego, San Diego, CA
| | - Yan Mee Law
- Department of Radiology Singapore General Hospital, Singapore
| | - Lindsey Hazen
- Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Charisse Garcia
- Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Katie M. Merriman
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Tim E. Phelps
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Nathan S. Lay
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Antoun Toubaji
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Maria J. Merino
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Bradford J. Wood
- Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD
- Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Sandeep Gurram
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Peter L. Choyke
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Peter A. Pinto
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Baris Turkbey
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
9
|
Ramirez-Gil JG, Lopera AA, Garcia C. Calcium phosphate nanoparticles improve growth parameters and mitigate stress associated with climatic variability in avocado fruit. Heliyon 2023; 9:e18658. [PMID: 37576330 PMCID: PMC10412774 DOI: 10.1016/j.heliyon.2023.e18658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 07/17/2023] [Accepted: 07/24/2023] [Indexed: 08/15/2023] Open
Abstract
The avocado cv. Hass is one of the most dynamic fruits in the world and is of particular significance in tropical areas, where climate variability phenomena have a high impact on productivity and sustainability. Nanotechnology-based tools could be an alternative to mitigate and/or adapt plants to these phenomena. Our approach was based on identifying changes in temperature and precipitation associated with climate variability in avocado areas in Colombia and proposing mitigation strategies based on the use of nanotechnology. This study had two objectives: (i) to identify variations in temperature and precipitation in avocado-producing areas in Colombia and (ii) to evaluate the effect of calcium phosphate nanoparticles (nano CP) as an alternative to reduce stress in avocados under simulate climatic variability condition. Climatic clusters were determined based on the spatial K-means method and with the climatic temporal series data (1981-2020), a time series analysis we carried out. Later changes in each cluster were simulated in growth chambers, evaluating physiological and developmental responses in avocado seedlings subjected to nanoCaP after adjusting the application form and dose. XRD diffraction shows that the calcium phosphate phases obtained by solution combustion correspond to a mixture of hydroxyapatite and witocklite nanoparticles with irregular morphologies and particle sizes of 100 nm. Three clusters explained ∼90% of the climate variation, with increases and decreases in temperature and precipitation in the range of 1-1.4 °C and 4.1-7.3% respectively. The best-fitted time series models were of stationary autoregressive integrated moving averages (SARIMA). The avocado seedlings had differential responses (P<0.05) depending on the clusters, with a decrease in physiological behavior and development between 10 and 35%. Additionally, the nanoCaP reduced the climatic stress (P< 0.05) in a range between 10 and 22.5%. This study identified the negative effect of climate variability on avocado seedlings and how nanoCaP can mitigate these phenomena.
Collapse
Affiliation(s)
- Joaquin Guillermo Ramirez-Gil
- Universidad Nacional de Colombia Sede Bogotá, Facultad de Ciencias Agrarias, Departamento de Agronomía, Colombia
- Laboratorio de Agrocomputación y Análisis epidemiológico, Center of Excellence in Scientific Computing, Universidad Nacional de Colombia, Bogotá 111321, Colombia
| | - Alex A. Lopera
- Grupo de Nanoestructuras y Física Aplicada (NANOUPAR), Dirección Académica, Universidad Nacional de Colombia, Sede de La Paz, Km 9 vía Valledupar La Paz, La Paz 202010, Colombia
| | - C. Garcia
- Universidad Nacional de Colombia, Sede Medellin, Carrera 65 # 59A-100, Medellín 050034, Colombia
| |
Collapse
|
10
|
Yilmaz EC, Shih JH, Belue MJ, Harmon SA, Phelps TE, Garcia C, Hazen LA, Toubaji A, Merino MJ, Gurram S, Choyke PL, Wood BJ, Pinto PA, Turkbey B. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers. Radiology 2023; 307:e221309. [PMID: 37129493 PMCID: PMC10323290 DOI: 10.1148/radiol.221309] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 01/21/2023] [Accepted: 02/10/2023] [Indexed: 05/03/2023]
Abstract
Background Data regarding the prospective performance of Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 alone and in combination with quantitative MRI features for prostate cancer detection is limited. Purpose To assess lesion-based clinically significant prostate cancer (csPCa) rates in different PI-RADS version 2.1 categories and to identify MRI features that could improve csPCa detection. Materials and Methods This single-center prospective study included men with suspected or known prostate cancer who underwent multiparametric MRI and MRI/US-guided biopsy from April 2019 to December 2021. MRI scans were prospectively evaluated using PI-RADS version 2.1. Atypical transition zone (TZ) nodules were upgraded to category 3 if marked diffusion restriction was present. Lesions with an International Society of Urological Pathology (ISUP) grade of 2 or higher (range, 1-5) were considered csPCa. MRI features, including three-dimensional diameter, relative lesion volume (lesion volume divided by prostate volume), sphericity, and surface to volume ratio (SVR), were obtained from lesion contours delineated by the radiologist. Univariable and multivariable analyses were conducted at the lesion and participant levels to determine features associated with csPCa. Results In total, 454 men (median age, 67 years [IQR, 62-73 years]) with 838 lesions were included. The csPCa rates for lesions categorized as PI-RADS 1 (n = 3), 2 (n = 170), 3 (n = 197), 4 (n = 319), and 5 (n = 149) were 0%, 9%, 14%, 37%, and 77%, respectively. csPCa rates of PI-RADS 4 lesions were lower than PI-RADS 5 lesions (P < .001) but higher than PI-RADS 3 lesions (P < .001). Upgraded PI-RADS 3 TZ lesions were less likely to harbor csPCa compared with their nonupgraded counterparts (4% [one of 26] vs 20% [20 of 99], P = .02). Predictors of csPCa included relative lesion volume (odds ratio [OR], 1.6; P < .001), SVR (OR, 6.2; P = .02), and extraprostatic extension (EPE) scores of 2 (OR, 9.3; P < .001) and 3 (OR, 4.1; P = .02). Conclusion The rates of csPCa differed between consecutive PI-RADS categories of 3 and higher. MRI features, including lesion volume, shape, and EPE scores of 2 and 3, predicted csPCa. Upgrading of PI-RADS category 3 TZ lesions may result in unnecessary biopsies. ClinicalTrials.gov registration no. NCT03354416 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Goh in this issue.
Collapse
Affiliation(s)
- Enis C. Yilmaz
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Joanna H. Shih
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Mason J. Belue
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Stephanie A. Harmon
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Tim E. Phelps
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Charisse Garcia
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Lindsey A. Hazen
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Antoun Toubaji
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Maria J. Merino
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Sandeep Gurram
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Peter L. Choyke
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Bradford J. Wood
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Peter A. Pinto
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| | - Baris Turkbey
- From the Molecular Imaging Branch (E.C.Y., M.J.B., S.A.H., T.E.P.,
P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and
Diagnosis (J.H.S.), Center for Interventional Oncology (C.G., L.A.H., B.J.W.),
Department of Radiology, Clinical Center (C.G., L.A.H., B.J.W.), Laboratory of
Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National
Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182,
Building 10, Room B3B85, Bethesda, MD 20892
| |
Collapse
|
11
|
Barman B, Linn AG, O'Beirne AL, Holleman J, Garcia C, Mapara V, Reno JL, McGill SA, Turkowski V, Karaiskaj D, Hilton DJ. Superradiant emission in a high-mobility two-dimensional electron gas. J Phys Condens Matter 2023; 35. [PMID: 37075774 DOI: 10.1088/1361-648x/acce8c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 04/19/2023] [Indexed: 05/03/2023]
Abstract
We use terahertz time-domain spectroscopy to study gallium arsenide two-dimensional electron gas samples in external magnetic field. We measure cyclotron decay as a function of temperature from 0.4 to10Kand a quantum confinement dependence of the cyclotron decay time belowT0=1.2K. In the wider quantum well, we observe a dramatic enhancement in the decay time due to the reduction in dephasing and the concomitant enhancement of superradiant decay in these systems. We show that the dephasing time in 2DEG's depends on both the scatteringrateand also on the distribution of scattering angles.
Collapse
Affiliation(s)
- B Barman
- College of Innovation and Technology, University of Michigan-Flint, Flint, MI 48502, United States of America
- Department of Physics, University of Alabama at Birmingham, Birmingham, AL 35294-1170, United States of America
| | - A G Linn
- Department of Physics, University of Alabama at Birmingham, Birmingham, AL 35294-1170, United States of America
| | - A L O'Beirne
- Department of Physics, University of Alabama at Birmingham, Birmingham, AL 35294-1170, United States of America
| | - J Holleman
- National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 30201, United States of America
| | - C Garcia
- National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 30201, United States of America
| | - V Mapara
- Department of Physics, University of South Florida, Tampa, FL 33620, United States of America
| | - J L Reno
- Center for Integrated Nanotechnologies, Sandia National Laboratory, Albuquerque, NM 87185, United States of America
| | - S A McGill
- National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 30201, United States of America
| | - V Turkowski
- Department of Physics, University of Central Florida, Orlando, FL 32816, United States of America
| | - D Karaiskaj
- Department of Physics, University of South Florida, Tampa, FL 33620, United States of America
| | - D J Hilton
- Department of Physics, Baylor University, Waco, TX 76798-7316, United States of America
| |
Collapse
|
12
|
Phelps TE, Yilmaz EC, Harmon SA, Belue MJ, Shih JH, Garcia C, Hazen LA, Toubaji A, Merino MJ, Gurram S, Choyke PL, Wood BJ, Pinto PA, Turkbey B. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions. Abdom Radiol (NY) 2023; 48:1079-1089. [PMID: 36526922 PMCID: PMC10765956 DOI: 10.1007/s00261-022-03775-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 12/07/2022] [Accepted: 12/08/2022] [Indexed: 12/23/2022]
Abstract
PURPOSE To evaluate the cancer detection rates of reduced-core biopsy schemes in patients with unilateral mpMRI-visible intraprostatic lesions and to analyze the contribution of systematic biopsy cores in clinically significant prostate cancer (csPCa) detection. METHODS 212 patients with mpMRI-visible unilateral intraprostatic lesions undergoing MRI/TRUS fusion-guided targeted biopsy (TBx) and systematic biopsy (SBx) were included. Cancer detection rates of TBx + SBx, as determined by highest Gleason Grade Group (GG), were compared to 3 reduced-core biopsy schemes: TBx alone, TBx + ipsilateral systematic biopsy (IBx; MRI-positive hemigland), and TBx + contralateral systematic biopsy (CBx; MRI-negative hemigland). Patient-level and biopsy core-level data were analyzed using descriptive statistics with confidence intervals. Univariable and multivariable logistic regression analysis was conducted to identify predictors of csPCa (≥ GG2) detected in MRI-negative hemiglands at p < 0.05. RESULTS Overall, 43.4% (92/212) of patients had csPCa and 66.0% (140/212) of patients had any PCa detected by TBx + SBx. Of patients with csPCa, 81.5% had exclusively ipsilateral involvement (MRI-positive), 7.6% had only contralateral involvement (MRI-negative), and 10.9% had bilateral involvement. The csPCa detection rates of reduced-core biopsy schemes were 35.4% (75/212), 40.1% (85/212), and 39.6% (84/212) for TBx alone, TBx + IBx, and TBx + CBx, respectively, with detection sensitivities of 81.5%, 92.4%, and 91.3% compared to TBx + SBx. CONCLUSION Reduced-core prostate biopsy strategies confined to the ipsilateral hemigland underestimate csPCa burden by at least 8% in patients with unilateral mpMRI-visible intraprostatic lesions. The combined TBx + SBx strategy maximizes csPCa detection.
Collapse
Affiliation(s)
- Tim E Phelps
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Enis C Yilmaz
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Stephanie A Harmon
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Mason J Belue
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Joanna H Shih
- Biometric Research Program, National Cancer Institute, NIH, Rockville, MD, USA
| | - Charisse Garcia
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA
- Department of Radiology, Clinical Center, NIH, Bethesda, MD, USA
| | - Lindsey A Hazen
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA
- Department of Radiology, Clinical Center, NIH, Bethesda, MD, USA
| | - Antoun Toubaji
- Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Sandeep Gurram
- Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Peter L Choyke
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Bradford J Wood
- Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA
- Department of Radiology, Clinical Center, NIH, Bethesda, MD, USA
| | - Peter A Pinto
- Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Baris Turkbey
- Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
- Molecular Imaging Branch, National Cancer Institute, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, MD, 20892-1088, USA.
| |
Collapse
|
13
|
Bazewicz M, Makhoul D, Goffin L, El Mouden J, Judice M Relvas L, Caspers L, Draganova D, Postelmans L, Garcia C, Willermain F. Clinical Utility of 18F-FDG PET/CT in the Work-up of Children with Uveitis. Ocul Immunol Inflamm 2023; 31:77-86. [PMID: 35113746 DOI: 10.1080/09273948.2021.1985522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
PURPOSE To evaluate 18F-fluorodeoxyglucose Positron Emission Tomography/ultra low dose Computed Tomography (18F-FDG PET/ ULD CT) in the work-up of pediatric uveitis. METHODS Retrospective study of 12 children followed for uveitis who underwent whole body 18F-FDG PET/ULD CT between 2011 and 2019. RESULTS The average age of the patients was 11 years. A total of 100% of patients presented with bilateral uveitis, 50% had panuveitis and 92% had various choroidal involvement. Relevant information for diagnosis was provided in four patients. 5/12 had an abnormal 18F-FDG uptake. Of these, three patients had pathognomonic images of active granulomatous diseases. Three patients underwent PET CT-guided biopsies of which two were positive for sarcoidosis. CONCLUSION 18F-FDG PET/CT provided important information for final diagnosis in approximately 30% (4/12) of pediatric patients with bilateral uveitis. Whole body FDG PET/ULD CT can contribute to the final diagnosis thanks to pathognomonic image of active granulomatous disease and/or by indicating metabolically active site of biopsy that would not be visualized in thorax CT.
Collapse
Affiliation(s)
- M Bazewicz
- Ophthalmology, CHU Saint Pierre and CHU Brugmann, Brussels, Belgium
| | - D Makhoul
- Ophthalmology, CHU Saint Pierre, Brussels, Belgium
| | - L Goffin
- Pediatry, Queen Fabiola Children's University Hospital, Brussels, Belgium
| | - J El Mouden
- Ophthalmology, CHU Brugmann, Brussels, Belgium
| | | | - L Caspers
- Ophthalmology, CHU Saint Pierre, Brussels, Belgium
| | - D Draganova
- Ophthalmology, CHU Saint Pierre and CHU Brugmann, Brussels, Belgium
| | | | - C Garcia
- Nuclear Medicine, CHU Saint Pierre, Université Libre De Bruxelles, Brussels, Belgium
| | - F Willermain
- Ophthalmology, CHU Saint-Pierre and CHU Brugmann, Université Libre De Bruxelles, Brussels, Belgium
| |
Collapse
|
14
|
Wallace AS, Ryman TK, Privor-Dumm L, Morgan C, Fields R, Garcia C, Sodha SV, Lindstrand A, Nic Lochlainn LM. Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030. Vaccine 2022:S0264-410X(22)01452-9. [PMID: 36503859 PMCID: PMC10414185 DOI: 10.1016/j.vaccine.2022.11.039] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 10/12/2022] [Accepted: 11/17/2022] [Indexed: 12/13/2022]
Abstract
Strategic Priority 4 (SP4) of the Immunization Agenda 2030 aims to ensure that all people benefit from recommended immunizations throughout the life-course, integrated with essential health services. Therefore, it is necessary for immunization programs to have coordination and collaboration across all health programs. Although there has been progress, immunization platforms in the second year of life and beyond need continued strengthening, including booster doses and catch-up vaccination, for all ages, and recommended vaccines for older age groups. We note gaps in current vaccination programs policies and achieved coverage, in the second year of life and beyond. In 2021, the second dose of measles-containing vaccine (MCV2), given in the second year of life, achieved 71% global coverage vs 81% for MCV1. For adolescents, 60% of all countries have adopted human papillomavirus vaccines in their vaccination schedule with a global coverage rate of only 12 percent in 2021. Approximately 65% of the countries recommend influenza vaccines for older adults, high-risk adults and pregnant women, and only 25% recommended pneumococcal vaccines for older adults. To achieve an integrated life course approach to vaccination, we reviewed the evidence, gaps, and strategies in four focus areas: generating evidence for disease burden and potential vaccine impact in older age groups; building awareness and shifting policy beyond early childhood; building integrated delivery approaches throughout the life course; and identifying missed opportunities for vaccination, implementing catch-up strategies, and monitoring vaccination throughout the life course. We identified needs, such as tailoring strategies to the local context, conducting research and advocacy to mobilize resources and build political will. Mustering sufficient financial support and demand for an integrated life course approach to vaccination, particularly in times of COVID-19, is both a challenge and an opportunity.
Collapse
Affiliation(s)
- A S Wallace
- Centers for Disease Control and Prevention, Atlanta, GA, United States.
| | - T K Ryman
- Bill and Melinda Gates Foundation, Seattle, WA, United States
| | - L Privor-Dumm
- Johns Hopkins Bloomberg School of Public Health, International Vaccine Access Center, Baltimore, MD, United States
| | - C Morgan
- Jhpiego, the Johns Hopkins University affiliate, Baltimore, MD, United States
| | - R Fields
- John Snow Inc., Arlington, VA, United States
| | - C Garcia
- Johns Hopkins Bloomberg School of Public Health, International Vaccine Access Center, Baltimore, MD, United States
| | - S V Sodha
- Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland
| | - A Lindstrand
- Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland
| | - L M Nic Lochlainn
- Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland
| |
Collapse
|
15
|
Harte G, Keane J, Ryan D, Collins R, Garcia C, Howlin R, Ryan S, Connolly A, Leitch E, Moynan W, Healy S, Keenan M. 321 UNMET NEEDS AFTER STROKE. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Unmet needs, such as lack of access to rehabilitation, support and information, are experienced by a high proportion of stroke survivors after discharge from acute and rehabilitation services. The UK guidelines on stroke (2016) recommend that all patients should be offered a structured health and social care review at 6 months post-stroke. However, no such clinics exist to date in Ireland. We aimed to explore the extent of unmet needs in the catchment area of a large teaching hospital.
Methods
A random selection of patients 6-months post-stroke were contacted by telephone and unmet needs were assessed using a validated tool, Post-Stroke Checklist. Following analysis of data, the need for a pilot clinic was identified. A separate random selection of patients discharged from acute services 6 months previously were invited to attend a review clinic. Patients were assessed using an adapted version of the Greater Manchester Stroke Assessment Tool. Assessments were conducted jointly by a physiotherapist and a speech and language therapist, and appropriate onward referrals were made.
Results
Telephone clinic: 51 patients completed the checklist. The most prevalent symptoms reported were fatigue (75%), reduced participation in hobbies and activities, decline in cognition (61%) and mobility problems (59%). Review clinic: 21 patients attended. The most prevalent symptoms reported were reduced memory/concentration (71%), low mood (71%), unintentional weight loss/gain (62%), and reduced mobility (43%). Onward referrals were made for in 16/21 (76%) cases; physiotherapy (n=12), occupational therapy (n=7), speech and language therapy (n=7), clinical nutrition (n=5), social work (n=7), psychology (n=5).
Conclusion
Data from this exploratory study supports previous research indicating a high number of stroke survivors with unmet needs. This highlights the importance of establishing post-acute stroke review clinics and pathways in the Irish setting.
Collapse
Affiliation(s)
- G Harte
- Tallaght University Hospital , Dublin, Ireland
| | - J Keane
- Tallaght University Hospital , Dublin, Ireland
| | - D Ryan
- Tallaght University Hospital , Dublin, Ireland
| | - R Collins
- Tallaght University Hospital , Dublin, Ireland
| | - C Garcia
- Tallaght University Hospital , Dublin, Ireland
| | - R Howlin
- Tallaght University Hospital , Dublin, Ireland
| | - S Ryan
- Tallaght University Hospital , Dublin, Ireland
| | - A Connolly
- Tallaght University Hospital , Dublin, Ireland
| | - E Leitch
- Tallaght University Hospital , Dublin, Ireland
| | - W Moynan
- Tallaght University Hospital , Dublin, Ireland
| | - S Healy
- Tallaght University Hospital , Dublin, Ireland
| | - M Keenan
- Tallaght University Hospital , Dublin, Ireland
| |
Collapse
|
16
|
Sommer-Trembo C, Oliver C, Wolf L, Garcia C, Salzburger W. Does the presence of conspecifics facilitate exploratory behaviour in a cichlid fish (Etroplus suratensis)? BEHAVIOUR 2022. [DOI: 10.1163/1568539x-bja10156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Abstract
Animals confronted with any kind of novelty show behavioural responses driven by avoidance and exploration. The expression of both tendencies is modulated by anxiety. Especially in group-living animals, the presence of conspecifics can reduce anxiety in novel situations and hence increase exploratory tendency. Such intensified behavioural responses triggered by the social environment of an individual are called social facilitation. Here, we tested for social facilitation on the exploratory tendency of group-living juvenile Green chromide cichlid fish (Etroplus suratensis) by assessing each individual twice in an open field test: once alone and once together with a conspecific. Contrary to our expectations, we found no difference in exploratory behaviour between the groups. However, our results suggest that changes in exploratory tendency across the two treatments were highly individual, both in extent and direction, and are likely driven by the presence of the conspecific and the focal individual’s own behavioural type.
Collapse
Affiliation(s)
- C. Sommer-Trembo
- Department of Environmental Sciences, Zoological Institute, University of Basel, Basel, Switzerland
| | - C. Oliver
- Department of Environmental Sciences, Zoological Institute, University of Basel, Basel, Switzerland
| | - L. Wolf
- Department of Environmental Sciences, Zoological Institute, University of Basel, Basel, Switzerland
| | - C. Garcia
- Department of Environmental Sciences, Zoological Institute, University of Basel, Basel, Switzerland
| | - W. Salzburger
- Department of Environmental Sciences, Zoological Institute, University of Basel, Basel, Switzerland
| |
Collapse
|
17
|
López-Hernández I, Truttmann V, Garcia C, Lopes C, Rameshan C, Stöger-Pollach M, Barrabés N, Rupprechter G, Rey F, Palomares A. AgAu nanoclusters supported on zeolites: Structural dynamics during CO oxidation. Catal Today 2022. [DOI: 10.1016/j.cattod.2021.04.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
18
|
Bize C, Le Gelebart E, Garcia C. 144 An innovative moisturizer to break inflamm’dryness vicious circle. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Capela AB, Antunes P, Coelho A, Amorim R, Custodio S, Amarelo A, Silva J, Vilela E, Tavares A, Costa T, Garcia C, Catarino J, Travassos B, Mendes R, Joaquim A, Teixeira M, Viamonte S, Figueiredo P, Brito J, Alves A. 1682P Effects of a walking football program on muscle strength and balance of androgen deprived prostate cancer patients: The Prostata_Move trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Leao I, Garcia C, Antunes P, Campolargo A, Dias I, Coimbra E, Zenha H, Castro J, Oliveira P, Giesteira M, Costa H, Alves A, Capela A, Joaquim A. 918P Impact of locally advanced head and neck cancer treatment: Is there a role for exercise? FIT4TREAT. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
21
|
Piccolomini M, Garcia C, Turco EL, Massaia I, Orteiro M, Duarte O, Yamakami L, Miyadahira E, Prado F. P–272 The aneuploid embryo secretome. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Does the metabolomic analysis of the embryonic culture medium predict the embryo aneuploidy?
Summary answer
The presence and quantity of some metabolites in the culture medium can select euploid embryos for transfer.
What is known already
Advances in analytical techniques for metabolomics have brought the possibility of better tools for the characterization of molecules. Embryonic metabolism can be used as a good indicator of viability, regardless of the morphology of the blastocysts, since differences were observed in the metabolic activities between the days of embryo development and in the rates of live births.
Study design, size, duration
17 patients had their embryos biopsied between January to July 2019 in a human reproduction laboratory. All cases had PGT-A indication and after the biopsy, the embryos were frozen. The culture medium samples were individually prepared for metabolites extraction according to the Bligh and Dyer protocol. Controlled ovarian stimulation and dose adjustments according to the response of each patient. The metabolomics analysis was performed by mass spectrometry.
Participants/materials, setting, methods
Ovum pick up will be performed 35 hours after r-hCG administration. The embryos were kept in individual 50ul drops until the blastocyst stage. The biopsy was performed in 26 blastocysts. The samples were sent to the 337 metabolites analysis by mass spectrometry. 15 molecules with the highest score on the PLS-Da was submitted the ROC curves to illustrate the power of the metabolic ploidy analysis. Besides, we performed the functional enrichment analysis for each group.
Main results and the role of chance
After the genetic analysis by PGT-a, 10 aneuploid embryos and 16 euploid embryos were found. Comparing the quantitative target metabolomic analysis of the 337 metabolites in the embryo culture medium, we observed the L-Alanine, Cytosine, Guanosine monophosphate, Homocysteine, Hypoxanthine, and Xanthine hiperrepresented in the aneuploid embryos, and the Citrulline, L-Glutamic acid, Kynurenine, L-Leucine, Methionine, Ornithine, L-Phenylalanine, L-Tyrosine, L-Valine were hiperrepresented in the euploid embryos. Through the ROC curve, we can verify AUC = 0.987. This result suggests that the analysis of euploid embryos through the metabolomic analysis of the culture medium is valid to be used as a noninvasive aneuploid diagnostic. The functional enrichment analysis shows the urea cycle and the glycine and serine metabolism as the principal function alter by aneuploid.
Limitations, reasons for caution
Small number of samples and not validate sample group.
Wider implications of the findings: Further studies are needed to validate these findings for the diagnostic of embryo euploidy.
Trial registration number
N/A
Collapse
Affiliation(s)
| | - C Garcia
- Lab For Life, Embryology, São Paulo, Brazil
| | - E L Turco
- UNIFESP, Urologia, São Paulo, Brazil
| | - I Massaia
- Faculdade de Medicina da Santa casa de São Paulo, Clinica Médica, São Paulo, Brazil
| | - M Orteiro
- Lab For Life, Embryology, São Paulo, Brazil
| | - O Duarte
- Lab For Life, Clinica Médica, São Paulo, Brazil
| | - L Yamakami
- Vida Bem Vinda, Clinica Médica, São Paulo, Brazil
| | - E Miyadahira
- Vida Bem Vinda, Clinica Médica, São Paulo, Brazil
| | - F Prado
- Lab For Life, Clinica Médica, São Paulo, Brazil
| |
Collapse
|
22
|
Orteiro M, Piccolomini M, Garcia C, Massaia I, Alvarenga A, Turco EL, Duarte O, Yamakami L. P–170 The secretomy of embryo sex. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does the analysis of the metabolites of the embryonic culture medium can predict the sex of the embryo?
Summary answer
The presence and quantity of some metabolites in the culture medium can predict the sex of the human embryos.
What is known already
Advances in analytical techniques for metabolomics have brought the possibility of better tools for the characterization of molecules. Embryonic metabolism can be used as a good indicator of viability, regardless of the morphology of the blastocysts, since differences were observed in the metabolic activities between the days of embryo development and in the rates of live births.
Study design, size, duration
16 patients had their embryos biopsied between the months of January to July 2019 in a human reproduction laboratory. All cases had PGT-A indication and after the biopsy, the embryos were frozen. The culture medium samples were individually prepared for metabolites extraction according to the Bligh and Dyer protocol. Controlled ovarian stimulation and dose adjustments according to the response of each patient. The metabolomics analysis was performed by mass spectrometry.
Participants/materials, setting, methods
Follicular puncture were performed 35 hours after r-hCG. The eggs were kept in individual culture until the blastocyst stage. The blastocysts biopsy was performed (20). After the culture medium was sent to the 337 metabolites analysis by mass spectrometry. 14 molecules with the highest score on the PLS-Da was submitted to the ROC curves showing the power of metabolic analysis to predict the sex of euploid embryos. Besides, we performed the functional enrichment analysis.
Main results and the role of chance
After the genetic analysis by PGT-a, we obtain 20 euploid embryos, being 12 female embryos and 08 male embryos. Comparing the quantitative target metabolomic analysis of the 337 metabolites in the embryo culture medium, we observed the Asymmetric dimethylarginine, FAD, Malic Acid, Serotonin, increased in female embryos and Adenosine monophosphate, L-Alanine, L-Arginine, Cysteamine, DL-Dopa, Flavin Mononucleotide, Methionine sulfone, Nicotinic acid, L-Tyrosine, Uracil in male embryos. Through the ROC curve, we can verify AUC = 0.937. This result suggests that the metabolomic analysis of the culture medium is valid to be used as a complement of PGT-A to know embryo sex diagnostic. The functional enrichment analysis shows the Asymmetric dimethylarginine and Malic Sulfone metabolism as the principal function alter by female embryos.
Limitations, reasons for caution
Small number of samples
Wider implications of the findings: Further studies are needed to validate these findings for the diagnostic of sex embryos
Trial registration number
N/A
Collapse
Affiliation(s)
- M Orteiro
- Lab For Life, Embryology, São Paulo, Brazil
| | | | - C Garcia
- Lab For Life, Embryology, São Paulo, Brazil
| | - I Massaia
- Faculdade de Medicina da Santa casa de São Paulo, Clinica Médica, São Paulo, Brazil
| | | | - E. L Turco
- UNIFES/EmbrioLogica, Urologia, Sao Paulo, Brazil
| | - O Duarte
- Lab For Life, Clinical, São Paulo, Brazil
| | - L Yamakami
- Vida Bem Vinda Clinic, Clinical, São Paulo, Brazil
| |
Collapse
|
23
|
Cerrolaza M, Sanagustin P, Lanzuela M, Ibañez R, Campos A, Flamarique S, Garcia C, Escuin C, Navarro V, Lanuza A. PO-1411 Electronic skin cancer brachytherapy: our experience and first outcomes. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07862-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Cerrolaza M, Sanagustin P, Ibañez R, Campos A, Flamarique S, Garcia C, Escuin C, Navarro V, Lanuza A, Lanzuela M. PO-1412 Superficial radiotherapy in the treatment of non-melanoma skin cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07863-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Cerrolaza M, Sanagustin P, Ibañez R, Campos A, Flamarique S, Garcia C, Escuin C, Navarro V, Lanuza A. PO-1496 Superficial X-Ray Therapy in Keloids after surgery: our experience. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07947-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Lopes S, Mesquita-Bastos J, Garcia C, Figueiredo D, Carvalho P, Oliveira J, Polonia J, Alves AJ, Ribeiro F. May the brief physical activity assessment tool accurately measure physical activity in patients with resistant hypertension? Eur J Cardiovasc Nurs 2021. [DOI: 10.1093/eurjcn/zvab060.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – EU funding. Main funding source(s): FEDER Funds through the Operational Competitiveness Factors Program—COMPETE National Funds through the Portuguese Foundation for Science and Technology (FCT) “PTDC/DTP-DES/1725/2014”. SL is a PhD fellow supported by the FCT (Grant Ref: SFRH/BD/129454/2017).
Introduction
Resistant hypertension is a major health problem due to the increased risk of cardiovascular events and mortality. Physical activity and exercise reduces blood pressure in resistant hypertension and is associated with lower cardiovascular risk and mortality. It is presently recommended that physical activity assessment should be a priority in all visits to health settings
Purpose
This study aims to determine if the Brief Physical Activity Assessment Tool (BPAAT), a 2-question tool to assess physical activity, is a valid instrument to detect inactive patients with resistant hypertension.
Methods
Sixty patients with a diagnosis of resistant hypertension were recruited. Outcome measures included clinical data, blood pressure and daily physical activity. Physical activity was objectively measured over a 7-day period with an accelerometer and subjectively assessed (self-assessment) by the BPAAT. The association between the BPAAT and accelerometry, according to the BPAAT scoring categories, was assessed bythe percentage of agreement, Cohen’s Kappa and sensitivity and specificity.
Results
Patients (33 were male) had a mean age of 59.4 ± 9.1years, were on average overweight (BMI 29.5 ± 4.5 kg/m2) and on an average of 4.5 ± 0.7 antihypertensive medications. Forty-two patients (70%) were classified as insufficiently active by the BPAAT compared to the 38 (63.3%) insufficiently active patients identified by the accelerometry data. Regarding the questionnaire’s specificity and sensitivity, the BPAAT correctly identified 32 [84.2 (73.1 – 95.3) %] of the 38 ‘insufficiently active’ patients and 12 [54.5 (34.3 – 74.7) %] of the 22 ‘sufficiently active’ patients identified by accelerometry. The agreement between BPAAT and accelerometry to identify sufficiently/insufficiently active patients, according to the BPAAT’s cut-off values was fair to moderate (Kappa = 0.403 (0.162 – 0.674), with a percentage of agreement of 73.3%.
Conclusion
The BPAAT, a 2-question tool to assess physical activity, seems to be a valid and fast solution to identify insufficiently active adults with resistant hypertension during routine clinical visits.
Collapse
Affiliation(s)
- S Lopes
- University of Aveiro, iBiMED - Institute of Biomedicine, School of Health Sciences, Aveiro, Portugal
| | - J Mesquita-Bastos
- Centro Hospitalar do Baixo Vouga, Cardiology Department, Hospital Infante D.Pedro, Aveiro, Portugal
| | - C Garcia
- University Institute of Maia, Research Center in Sports Sciences, Health and Human Development, CIDESD, Maia, Portugal
| | - D Figueiredo
- University of Aveiro, School of Health Sciences and CINTESIS@UA, Aveiro, Portugal
| | - P Carvalho
- Centro Hospitalar do Baixo Vouga, Cardiology Department, Hospital Infante D.Pedro, Aveiro, Portugal
| | - J Oliveira
- University of Porto, Research Centre in Physical Activity, Health and Leisure, Faculty of Sport, , Porto, Portugal
| | - J Polonia
- Faculty of Medicine University of Porto, Hypertension Unit, ULS Matosinhos, Porto, Portugal
| | - AJ Alves
- University Institute of Maia, Research Center in Sports Sciences, Health and Human Development, CIDESD, Maia, Portugal
| | - F Ribeiro
- University of Aveiro, iBiMED - Institute of Biomedicine, School of Health Sciences, Aveiro, Portugal
| |
Collapse
|
27
|
Lopes S, Mesquita-Bastos J, Garcia C, Leitao C, Bertoquini S, Ribau V, Carvalho P, Oliveira J, Viana J, Figueiredo D, Guimaraes GV, Polonia J, Alves AJ, Ribeiro F. Higher levels of physical activity is associated with lower arterial stiffness in patients with resistant hypertension. Eur J Cardiovasc Nurs 2021. [DOI: 10.1093/eurjcn/zvab060.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): Portuguese Foundation for Science and Technology (FCT) European Regional Development Fund – Operational Competitiveness Factors Program (COMPETE)
Background
Physical activity has been associated with reduced arterial stiffness in patients with hypertension. However, in resistant hypertension, a specific population with an increased risk for target organ damage, cardiovascular morbidity, and mortality, the evidence is sparse.
Purpose
The present study aimed to determine the association between daily physical activity and arterial stiffness in patients with resistant hypertension.
Methods
Fifty-seven patients with resistant hypertension were recruited. Physical activity was objectively assessed during 7 consecutive days with accelerometers. Arterial stiffness was evaluated using carotid-femoral pulse wave velocity (cf-PWV) .
Results
Participants (50.9% men), aged 58.8 ± 9.4 years, were mainly overweight and were taking in average 4.5 antihypertensive medications. The cf-PWV showed an inverse correlation with light-intensity physical activity (r = -0.290, p = 0.029) and total daily physical activity (r = -0.287, p = 0.030). Additionally, cf-PWV tended to be inversely associated with the number of steps per day (r = -0.242, p = 0.069). Patients with higher risk of cardiovascular events (cf-PWV ≥ 10 m/s) tended to spend less time in light-intensity physical activity (324.0 ± 129.4 vs. 380.5 ± 103.1 min/day, p = 0.090) and to perform less total daily physical activity (351.5 ± 141.7 vs. 411.7 ± 109.1 min/day, p = 0.091) than participants with cf-PWV below the risk threshold value.
Conclusions
Higher levels of total physical activity and daily levels of light-intensity were associated to lower arterial stiffness. These results emphasize the importance of physical activity as a nonpharmacological tool for patients with resistant hypertension.
Collapse
Affiliation(s)
- S Lopes
- University of Aveiro, Aveiro, Portugal
| | - J Mesquita-Bastos
- University of Aveiro, iBiMED - Institute of Biomedicine, School of Health Sciences, Aveiro, Portugal
| | - C Garcia
- University Institute of Maia, Research Center in Sports Sciences, Health and Human Development, CIDESD, Maia, Portugal
| | - C Leitao
- University of Aveiro, I3N, Department of Physics, Aveiro, Portugal
| | - S Bertoquini
- Faculty of Medicine University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal
| | - V Ribau
- Centro Hospitalar do Baixo Vouga, Cardiology Department, Hospital Infante D.Pedro, Aveiro, Portugal
| | - P Carvalho
- Centro Hospitalar do Baixo Vouga, Cardiology Department, Hospital Infante D.Pedro, Aveiro, Portugal
| | - J Oliveira
- University of Porto, Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, Porto, Portugal
| | - J Viana
- University Institute of Maia, Research Center in Sports Sciences, Health and Human Development, CIDESD, Maia, Portugal
| | - D Figueiredo
- University of Aveiro, Center for Health Technology and Services Research (CINTESIS.UA), School of Health Sciences, Aveiro, Portugal
| | - GV Guimaraes
- Heart Institute of the University of Sao Paulo (InCor), School of Medicine, Sao Paulo, Brazil
| | - J Polonia
- Faculty of Medicine University of Porto, Center for Health Technology and Services Research (CINTESIS) & Hypertension and Cardiovascular Risk, Porto, Portugal
| | - AJ Alves
- University Institute of Maia, Research Center in Sports Sciences, Health and Human Development, CIDESD, Maia, Portugal
| | - F Ribeiro
- University of Aveiro, iBiMED - Institute of Biomedicine, School of Health Sciences, Aveiro, Portugal
| |
Collapse
|
28
|
Bolam SG, McIlwaine P, Garcia C. Marine macrofaunal traits responses to dredged material disposal. Mar Pollut Bull 2021; 168:112412. [PMID: 33930647 DOI: 10.1016/j.marpolbul.2021.112412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 04/16/2021] [Accepted: 04/18/2021] [Indexed: 06/12/2023]
Abstract
Currently, our understanding of the mechanisms for, and potential functional implications of, changes in seabed assemblages resulting from dredged material disposal is relatively unknown. Based on empirical data from 17 disposal sites, we address this by quantifying the nature and magnitude of shifts in the relative composition of response and effects traits within disposal site assemblages relative to their reference assemblages. Differing shifts in both response and effects traits were observed across sites, regardless of the trait composition of the reference assemblages. Notable differences in the magnitude of traits changes were also observed for both trait types. Traits shifts are difficult to predict as they appear to reflect both environmental conditions and disposal regime. Temporal data revealed that some sites display relatively consistent responses while others presented large inter-annual variability. These findings are discussed in relation to dredged material monitoring and with respect to conservation objectives of marine protected areas.
Collapse
Affiliation(s)
- S G Bolam
- The Centre for Environment, Fisheries and Aquaculture Science, Pakefield Road, Suffolk NR33 0HT, UK.
| | - P McIlwaine
- The Centre for Environment, Fisheries and Aquaculture Science, Pakefield Road, Suffolk NR33 0HT, UK
| | - C Garcia
- The Centre for Environment, Fisheries and Aquaculture Science, Pakefield Road, Suffolk NR33 0HT, UK
| |
Collapse
|
29
|
Herranz P, Trasobares L, Mateu A, Martínez E, Ruiz-Villaverde R, Baniandrés O, Mataix Díaz J, Jiménez-Gómez N, Serra M, Ruiz Genao DP, Rivera N, Tercedor-Sánchez J, Garcia C, Cordey M, Herrera-Acosta E. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study. Actas Dermosifiliogr (Engl Ed) 2021; 112:S0001-7310(21)00202-7. [PMID: 34052202 DOI: 10.1016/j.ad.2021.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 04/29/2021] [Accepted: 05/09/2021] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND AND OBJECTIVES It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. METHODS Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (±1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. RESULTS A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). CONCLUSIONS Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials.
Collapse
Affiliation(s)
- P Herranz
- Hospital Universitario La Paz, Madrid, España.
| | - L Trasobares
- Hospital Universitario Príncipe de Asturias, Madrid, España
| | - A Mateu
- Hospital Universitario Doctor Peset, Valencia, España
| | - E Martínez
- Hospital Lluís Alcanyís Xàtiva, Valencia, España
| | | | - O Baniandrés
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | | | | | - M Serra
- Hospital Can Misses, Illes Balears, España
| | | | - N Rivera
- Hospital de Mollet, Barcelona, España
| | | | | | - M Cordey
- Amgen Inc., Amgen (Europe) GmbH, Rotkreuz, Suiza
| | | |
Collapse
|
30
|
Hernandez E, Anchartéchahar V, Kern C, Garcia C. 627 Effect of titrated extract of centella asiatica on skin repair process. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Gadea J, Ortiz I, Roncero R, Alastuey I, Mestre F, Aymar N, Maturana JE, Garcia C, Mateu L, Pardo J. Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes. Clin Transl Oncol 2021; 23:1915-1922. [PMID: 33830442 PMCID: PMC8026808 DOI: 10.1007/s12094-021-02600-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 03/15/2021] [Indexed: 11/20/2022]
Abstract
Background and purpose Synchronous bilateral breast cancer (SBBC) accounts for 1–3.5% of breast cancer patients. The aim of this study was to evaluate dosimetric issues, clinical outcomes, and acute toxicities for SBBC patients receiving synchronous bilateral hypofractionated radiotherapy (SBHRT) and to compare them with patients treated with synchronous bilateral normofractionated RT schedule (SBNRT). Materials and methods From April 2016 to March 2020, 39 SBBC patients were referred to our institution. Patients were divided according to their prescription dose: Group A: 50 Gy/25fx (fractions), B: 60–64 Gy/25fx, C: 40.05 Gy/15fx; D: 48 Gy/15fx. Toxicity was evaluated using Common Terminology Criteria for Adverse Events (CTCAE)v.5.0. Results 34 patients were finally evaluated. Median follow-up was 24 months for NF schedule and 9 months for HF schedule. In the HF schedule, no acute side-effects > G2 were observed and no dermatitis was reported in 6th month´s assessments. 95% of patients have no evidence of disease and only 1 patient presented local relapse in the first mammography after RT. No distant failures or deaths were observed. Regarding dosimetric issues, the inter-patient average Dmean for the heart was: Group A: 5.0 Gy (4.6–5.5), Group B: 4.4 Gy (4.1–5.4), Group C: 4.8 Gy (4.5–5.1) and Group D: 5.3 Gy (4.4–5.6). For the lungs, the inter-patient average Dmean was: Group A: 10.8 Gy (9.8–12.2), Group B: 11.5 Gy (11.3–12), Group C: 9.8 Gy (9.3–10.5) and Group D: 10.5 Gy (10–11.3). Conclusions This is the first study reporting the safety, feasibility, and tolerability of 40.05 Gy/15fx over 3 weeks for the treatment of SBBC patients. Further study with larger accrual is mandatory.
Collapse
Affiliation(s)
- J Gadea
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.
| | - I Ortiz
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.,Institut d´Investigació Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain
| | - R Roncero
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain
| | - I Alastuey
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.,Institut d´Investigació Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain
| | - F Mestre
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.,Institut d´Investigació Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain
| | - N Aymar
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.,Institut d´Investigació Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain
| | - J E Maturana
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain
| | - C Garcia
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain
| | - L Mateu
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain
| | - J Pardo
- Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain.,Institut d´Investigació Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain.,Hospital Universitari General de Catalunya, Sant Cugat del Vallés, Spain
| |
Collapse
|
32
|
Nañez A, Garcia C, Dontsi M, Powell C. Ovarian cancer in women with known BRCA mutations: How much screening is too much? Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Nevado P, Lopera A, Bezzon V, Fulla MR, Palacio J, Zaghete MA, Biasotto G, Montoya A, Rivera J, Robledo SM, Estupiñan H, Paucar C, Garcia C. Preparation and in vitro evaluation of PLA/biphasic calcium phosphate filaments used for fused deposition modelling of scaffolds. Mater Sci Eng C Mater Biol Appl 2020; 114:111013. [PMID: 32993985 DOI: 10.1016/j.msec.2020.111013] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 03/30/2020] [Accepted: 04/22/2020] [Indexed: 02/02/2023]
Abstract
Ceramic materials such as calcium phosphates (CaPs) with a composition similar to the mineral phase of bones and polymeric polylactic acid (PLA) are potential candidates for the manufacturing of scaffolds to act as bone substitutes and for tissue engineering applications, due to their bioresorbability and biocompatibility. Variables such as porosity, topography, morphology, and mechanical properties play an essential role in the scaffolds response. In this paper, a polymer/ceramic composite filament of 1.7 mm in diameter based on PLA and biphasic calcium phosphates (BCPs) was obtained by hot-melt extrusion in a single screw extruder. The particles of BCP were obtained by solution-combustion synthesis, and the PLA used was commercial grade. The BCPs ceramics were characterized by X-ray diffraction (XRD), scanning electron microscopic (SEM), transmission electron microscopy (TEM), and Brunauer, Emmett, and Teller (BET). It was possible to confirm that the main inorganic phases were hydroxyapatite (HAP) and tricalcium phosphate (TCP) with grain sizes below 100 nm and with high porosity. The Filaments obtained are a bit fragile but were able to be used in fused deposition modelling (FDM) using low-cost commercial printers. The filaments were characterized by SEM and energy dispersive X-ray (EDX). The in-vitro tests of filaments showed deposition of apatite phases on their surface, non-cytotoxic behavior, adequate cell proliferation and cell adhesion.
Collapse
Affiliation(s)
- P Nevado
- Grupo de Materiales Cerámicos y Vítreos, Escuela de Física Universidad Nacional de Colombia, Calle 59A.63-20, Medellín 050034, Colombia
| | - A Lopera
- Grupo de Materiales Cerámicos y Vítreos, Escuela de Física Universidad Nacional de Colombia, Calle 59A.63-20, Medellín 050034, Colombia; Grupo GICEI, Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Calle 73 No. 73A - 226, Medellín 050034, Colombia
| | - V Bezzon
- Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Santo André, SP, CEP 09210580, Brazil
| | - M R Fulla
- Grupo de Materiales Cerámicos y Vítreos, Escuela de Física Universidad Nacional de Colombia, Calle 59A.63-20, Medellín 050034, Colombia; Grupo GICEI, Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Calle 73 No. 73A - 226, Medellín 050034, Colombia
| | - J Palacio
- Grupo GICEI, Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Calle 73 No. 73A - 226, Medellín 050034, Colombia
| | - M A Zaghete
- LIEC, Institute of Chemistry, São Paulo State University-UNESP, Araraquara, SP 14800-060, Brazil
| | - G Biasotto
- LIEC, Institute of Chemistry, São Paulo State University-UNESP, Araraquara, SP 14800-060, Brazil
| | - A Montoya
- PECET-Instituto de Investigaciones Médicas, Universidad de Antioquia, Facultad de Medicina, Calle 62 No. 52-59, Medellín 050010, Colombia
| | - J Rivera
- Grupo GICEI, Institución Universitaria Pascual Bravo, Facultad de Ingeniería, Calle 73 No. 73A - 226, Medellín 050034, Colombia
| | - S M Robledo
- PECET-Instituto de Investigaciones Médicas, Universidad de Antioquia, Facultad de Medicina, Calle 62 No. 52-59, Medellín 050010, Colombia
| | - H Estupiñan
- Grupo de Investigación en Biosuperficies, Departamento de Materiales, Universidad Nacional de Colombia, Sede Medellín, Calle 59A.63-20, Medellín 050034, Colombia
| | - C Paucar
- Grupo de Materiales Cerámicos y Vítreos, Escuela de Física Universidad Nacional de Colombia, Calle 59A.63-20, Medellín 050034, Colombia
| | - C Garcia
- Grupo de Materiales Cerámicos y Vítreos, Escuela de Física Universidad Nacional de Colombia, Calle 59A.63-20, Medellín 050034, Colombia.
| |
Collapse
|
34
|
Nañez A, Powell C, Garcia C. Breast cancer after ovarian cancer in BRCA mutation carriers. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Torres Esteche V, Torres I, Aleman A, Soto J, Fernandez L, Romero L, Liencres A, Garcia C, Gutierrez M. CANNABIS CONSUMPTION RELATED TO CHRONIC AND ACUTE RESPIRATORY SYMPTOMS. Chest 2020. [DOI: 10.1016/j.chest.2020.05.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Haverinen-Shaughnessy U, Khan S, Boulafentis J, Garcia C, Shaughnessy R. Effects of educational efforts in tribal homes and schools to reduce asthma triggers, symptoms and missed school days. Int J Hyg Environ Health 2020; 228:113513. [PMID: 32311659 DOI: 10.1016/j.ijheh.2020.113513] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 02/21/2020] [Accepted: 03/16/2020] [Indexed: 12/16/2022]
Abstract
Native American asthma prevalence has been estimated higher than for the U.S. population average, and uncontrolled asthma results in absence from schools. This study analyzed effects of targeted education campaigns in both homes and schools on reducing asthma triggers and symptoms among 119 children with asthma, who were recruited from Cherokee and Nez Perce communities. The education campaigns were developed in collaboration with the researchers and the tribes, tailoring strategies to reduce asthma triggers adapted to tribal lifestyles. There was a special emphasis in identification of Traditional Ecological Knowledge (TEK) aspects, which were woven into the study plan and implementation. Some 62 study homes were investigated and the parents received targeted education at the beginning of the study, whereas the remaining control homes received the same education at the end of the study. In Cherokee homes, allergen levels were significantly increased in both control and study groups throughout the study. In Nez Perce homes, dog and cockroach allergen levels decreased significantly in the study homes. The parents reported asthma control test (ACT) scores of the children were significantly improved in both study and control groups, whereas respiratory illness days were reduced in the study group. In schools, allergen levels, particularly cat, dog and cockroach allergens, increased throughout the year in both study and control schools. However, high contact surface cleaning effectiveness based on adenosine tri phosphate (ATP) readings was improved in the study schools. It was also found that high contact surface cleaning effectiveness may have effects on students' absence rates tracked by schools. In conclusion, the results indicate partial improvements in parent reported health symptoms, although the improvements could not be definitively attributed to reduction of any specific exposure in the home environment. In the school environment, effective cleaning throughout the flu season could result in decreased absence rates.
Collapse
Affiliation(s)
| | - S Khan
- Cherokee Nation (Environmental Program and Health Services), Tahlequah, OK, USA
| | | | - C Garcia
- Nimiipuu Health, Lapwai, ID, USA
| | - R Shaughnessy
- The University of Tulsa, Indoor Air Program, Tulsa, OK, USA
| |
Collapse
|
37
|
Nañez A, Garcia C, Powell C. Ovarian Cancer in Women with Known BRCA Mutations: Does screening matter? Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
38
|
Nañez A, Langer S, Garcia C, Powell C. Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Gérardin B, Champagnac D, Smolka G, Bouvaist H, Jakamy R, Ghostine S, Naël J, Garcia C, Kloeckner M, Potier A, Isorni MA, Brenot P, Hascoet S. [Para valvular leak closure in TAVI]. Ann Cardiol Angeiol (Paris) 2019; 68:453-461. [PMID: 31733689 DOI: 10.1016/j.ancard.2019.09.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Literature concerning transcutaneous symptomatic para valvular cardiac leaks closure (PVLC) after trans aortic valve implantation (TAVI) is relatively scarce. Hereby we present 2 clinical cases, one on an Edwards® Sapien 3 valve and the other one on a Medtronic® Evolut R valve. We present also the preliminary results of the 7 PVLC on TAVI included in our prospective FFPP registry during the 2 first years of enrolment (2017-2018), for a total of 158 inclusions for all valves. Seven procedures were performed on 8 leaks, using a majority of vascular plugs (3 Abbott® Amplatzer Vascular Plugs 2 (AVP2), 3 AVP3, 1 AVP4, and 1 muscular Ventricular Septal Defect (VSD) occluder). All procedures were successful without complication. At 1-month follow-up, all patients became asymptomatic. One-year follow-up was already available for 4 patients: 3 of them were symptoms free, and one-who had a second leak not suitable for PVLC-, underwent a « TAVI in TAVI » procedure 2 months after PVLC. This short experience demonstrates the feasibility, the efficacy and the safety of PVLC on TAVI. We expect to be able to offer more in depth information at the end of our prospective ongoing study.
Collapse
Affiliation(s)
- B Gérardin
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | | | - G Smolka
- Medical University of Silesia, 40055 Katowice, Pologne
| | - H Bouvaist
- Centre hospitalo-universitaire de Grenoble, 38700 La-Tronche, France
| | - R Jakamy
- Centre hospitalo universitaire Haut-Lévêque, 33600 Pessac, France
| | - S Ghostine
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - J Naël
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - C Garcia
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - M Kloeckner
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - A Potier
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - M A Isorni
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - P Brenot
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| | - S Hascoet
- Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France
| |
Collapse
|
40
|
Joaquim A, Antunes P, Garcia C, Afreixo V, Amarelo A, Duarte B, Vieira M, Lopes R, Leão I, Baptista Capela A, Helguero L, Alves A. Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Marshall CR, Finnegan S, Clites EC, Holroyd PA, Bonuso N, Cortez C, Davis E, Dietl GP, Druckenmiller PS, Eng RC, Garcia C, Estes-Smargiassi K, Hendy A, Hollis KA, Little H, Nesbitt EA, Roopnarine P, Skibinski L, Vendetti J, White LD. Quantifying the dark data in museum fossil collections as palaeontology undergoes a second digital revolution. Biol Lett 2019; 14:rsbl.2018.0431. [PMID: 30185609 DOI: 10.1098/rsbl.2018.0431] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 08/06/2018] [Indexed: 11/12/2022] Open
Abstract
Large-scale analysis of the fossil record requires aggregation of palaeontological data from individual fossil localities. Prior to computers, these synoptic datasets were compiled by hand, a laborious undertaking that took years of effort and forced palaeontologists to make difficult choices about what types of data to tabulate. The advent of desktop computers ushered in palaeontology's first digital revolution-online literature-based databases, such as the Paleobiology Database (PBDB). However, the published literature represents only a small proportion of the palaeontological data housed in museum collections. Although this issue has long been appreciated, the magnitude, and thus potential significance, of these so-called 'dark data' has been difficult to determine. Here, in the early phases of a second digital revolution in palaeontology--the digitization of museum collections-we provide an estimate of the magnitude of palaeontology's dark data. Digitization of our nine institutions' holdings of Cenozoic marine invertebrate collections from California, Oregon and Washington in the USA reveals that they represent 23 times the number of unique localities than are currently available in the PBDB. These data, and the vast quantity of similarly untapped dark data in other museum collections, will, when digitally mobilized, enhance palaeontologists' ability to make inferences about the patterns and processes of past evolutionary and ecological changes.
Collapse
Affiliation(s)
- C R Marshall
- Department of Integrative Biology, University of California, 3040 Valley Life Sciences Building, Berkeley, CA 94720-3140, USA .,University of California Museum of Paleontology, University of California, 1101 Valley Life Sciences Building, Berkeley, CA 94720-4780, USA
| | - S Finnegan
- Department of Integrative Biology, University of California, 3040 Valley Life Sciences Building, Berkeley, CA 94720-3140, USA.,University of California Museum of Paleontology, University of California, 1101 Valley Life Sciences Building, Berkeley, CA 94720-4780, USA
| | - E C Clites
- University of California Museum of Paleontology, University of California, 1101 Valley Life Sciences Building, Berkeley, CA 94720-4780, USA
| | - P A Holroyd
- University of California Museum of Paleontology, University of California, 1101 Valley Life Sciences Building, Berkeley, CA 94720-4780, USA
| | - N Bonuso
- Department of Geological Sciences, California State University, Fullerton, CA 92834, USA
| | - C Cortez
- John D. Cooper Archaeological and Paleontological Center, Santa Ana, CA 92701-6427, USA
| | - E Davis
- Department of Earth Sciences, University of Oregon, Eugene, OR 97403-1272, USA.,University of Oregon Museum of Natural and Cultural History, 1680 E. 15th Avenue, Eugene, OR 97403-1224, USA
| | - G P Dietl
- Paleontological Research Institution, 1259 Trumansburg Road, Ithaca, NY 14850, USA.,Department of Earth and Atmospheric Sciences, Cornell University, 112 Hollister Drive, Ithaca, NY 14853, USA
| | - P S Druckenmiller
- University of Alaska Museum and Department of Geosciences, University of Alaska Fairbanks, 1962 Yukon Drive, Fairbanks, AK 99775, USA
| | - R C Eng
- Burke Museum of Natural History and Culture, University of Washington, Box 353010, Seattle, WA 98195-3010, USA
| | - C Garcia
- California Academy of Sciences, 55 Music Concourse Drive, San Francisco, CA 94118, USA
| | - K Estes-Smargiassi
- Natural History Museum of Los Angeles County, 900 Exposition Boulevard, Los Angeles, CA 90007, USA
| | - A Hendy
- Natural History Museum of Los Angeles County, 900 Exposition Boulevard, Los Angeles, CA 90007, USA
| | - K A Hollis
- Department of Paleobiology, National Museum of Natural History, Smithsonian Institution, PO Box 37012, Washington, DC 20013, USA
| | - H Little
- Department of Paleobiology, National Museum of Natural History, Smithsonian Institution, PO Box 37012, Washington, DC 20013, USA
| | - E A Nesbitt
- Burke Museum of Natural History and Culture, University of Washington, Box 353010, Seattle, WA 98195-3010, USA
| | - P Roopnarine
- California Academy of Sciences, 55 Music Concourse Drive, San Francisco, CA 94118, USA
| | - L Skibinski
- Paleontological Research Institution, 1259 Trumansburg Road, Ithaca, NY 14850, USA
| | - J Vendetti
- Natural History Museum of Los Angeles County, 900 Exposition Boulevard, Los Angeles, CA 90007, USA
| | - L D White
- University of California Museum of Paleontology, University of California, 1101 Valley Life Sciences Building, Berkeley, CA 94720-4780, USA
| |
Collapse
|
42
|
Cayrefourcq L, De Roeck A, Garcia C, Stoebner P, Fichel F, Garima F, Perriard F, Daures J, Meunier L, Alix-Panabieres C. 522 S100-EPISPOT: a new tool to detect viable circulating melanoma cells. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Llaó I, Gómez-Hospital JA, Aboal J, Garcia C, Montero S, Sambola A, Ortiz J, Tomás C, Bonet G, Viñas D, Oliveras T, Sans-Roselló J, Cantalapiedra J, Andrea R, Hernández I, Pérez-Rodriguez M, Gual M, Cequier A, Ariza-Solé A. Risk-adjusted early invasive strategy in patients with non-ST-segment elevation acute coronary syndrome in Intensive Cardiac Care Units. Med Intensiva 2019; 44:475-484. [PMID: 31362838 DOI: 10.1016/j.medin.2019.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 05/27/2019] [Accepted: 06/01/2019] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Current guidelines recommend a risk-adjusted early invasive strategy (EIS) in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). The present study assesses the application if this strategy, the conditioning factors and prognostic impact upon patients with NSTEACS admitted to Intensive Cardiac Care Units (ICCU). DESIGN A prospective cohort study was carried out. SETTING The ICCUs of 8 hospitals in Catalonia (Spain). PATIENTS Consecutive patients with NSTEACS between October 2017 and March 2018. The risk profile was defined by the European Society of Cardiology criteria. INTERVENTIONS EIS was defined as the performance of coronary angiography within the first 6hours in patients at very high-risk or within 24hours in high-risk patients. OUTCOME VARIABLES Mortality or readmission at 6 months. RESULTS A total of 629 patients were included (mean age 66.6 years), of whom 225 (35.9%) were at very high risk, and 392 (62.6%) at high risk. Most patients (96.2%) underwent an invasive strategy. EIS was performed in 284 patients (45.6%), especially younger patients with fewer comorbidities. These patients had a shorter ICCU and hospital stay, as well as a lesser incidence of ACS, revascularization and death or readmission at 6 months. After adjusting for confounders, the association between EIS and death or readmission at 6 months remained significant (hazard ratio: .66, 95% confidence interval .45-.97; P=.035). CONCLUSIONS The EIS was performed in a minority of NSTEACS admitted to ICCU, being associated with better outcomes.
Collapse
Affiliation(s)
- I Llaó
- Unidad de Cuidados Intensivos Cardiológicos, Servicio de Cardiología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - J A Gómez-Hospital
- Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - J Aboal
- Unidad de Cuidados Intensivos Cardiolígicos, Servicio de Cardiología, Hospital Universitari Josep Trueta, Girona, España
| | - C Garcia
- Unidad de Cuidados Intensivos Cardiolígicos, Servicio de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
| | - S Montero
- Unidad de Cuidados Intensivos Cardiológicos, Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica IIB Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, España
| | - A Sambola
- Unidad de Cuidados Intensivos cardiológicos. Hospital Universitari de la Vall d'Hebron, Barcelona, España
| | - J Ortiz
- Unidad de Cuidados Intensivos cardiológicos. Hospital Clínic i Provincial, Barcelona, España
| | - C Tomás
- Unidad de Cuidados Intensivos cardiológicos. Hospital Arnau de Vilanova, Lleida, España
| | - G Bonet
- Unidad de Cuidados Intensivos cardiológicos. Hospital Joan XXIII, Tarragona, España
| | - D Viñas
- Unidad de Cuidados Intensivos Cardiolígicos, Servicio de Cardiología, Hospital Universitari Josep Trueta, Girona, España
| | - T Oliveras
- Unidad de Cuidados Intensivos Cardiolígicos, Servicio de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
| | - J Sans-Roselló
- Unidad de Cuidados Intensivos Cardiológicos, Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica IIB Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, España
| | - J Cantalapiedra
- Unidad de Cuidados Intensivos Cardiolígicos, Servicio de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
| | - R Andrea
- Unidad de Cuidados Intensivos cardiológicos. Hospital Arnau de Vilanova, Lleida, España
| | - I Hernández
- Unidad de Cuidados Intensivos cardiológicos. Hospital Arnau de Vilanova, Lleida, España
| | - M Pérez-Rodriguez
- Unidad de Cuidados Intensivos cardiológicos. Hospital Joan XXIII, Tarragona, España
| | - M Gual
- Unidad de Cuidados Intensivos Cardiológicos, Servicio de Cardiología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - A Cequier
- Servicio de Cardiología. Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - A Ariza-Solé
- Unidad de Cuidados Intensivos Cardiológicos, Servicio de Cardiología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
| |
Collapse
|
44
|
Resende PC, Caetano B, Matos A, Lopes J, Garcia C, Miranda M, Born P, Motta FC, Brown D, Siqueira M. A31 Diversity change of influenza A (H3N2) strains circulating in Brazil during 2017–8: What to expect in the coming winter? Virus Evol 2019. [PMCID: PMC6735707 DOI: 10.1093/ve/vez002.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The H3N2 subtype of influenza A (H3N2) was the predominant strain during the early months of the 2017 influenza epidemic in Brazil. In Australia, it was responsible for a strong and prolonged 2017 season and reached the Northern hemisphere causing an intense 2017/8 influenza season. Several genetic and antigenic A(H3N2) variants were circulating, which made the decision about which strain to incorporate into the influenza vaccine challenging. For 2018, the WHO selected a new H3N2 strain, A/Singapore/INFIMH-16-0019/2016-like, to replace the strain A/HongKong/4801/2014-like in the Southern Hemisphere trivalent vaccine. The aim of this study was to describe the genetic diversity of influenza A (H3N2) viruses circulating in Brazil between January 2017 and January 2018, checking the match between the vaccines and worldwide circulating strains with the Brazilian influenza strains. Hemagglutinin gene sequencing of the influenza A (H3N2) was performed, followed by a phylogenetic reconstruction using additional database sequences to define genetic groups and compare with other worldwide circulating strains. We observed a large diversity of H3N2 genetic clusters, including 3C.2a, 3C.2a1, 3C.3a, and their subgroups. During the 2016–7, inter-epidemic and 2017 epidemic period the cluster most frequently detected belonged to clade 3C.2a1 (148/185; 80.0%), a distinct group related to the 2017 vaccine strain A/HongKong/4801/2014-like (3C.2a). However, the genetic profile changed during the study period and in the inter-epidemic season 2017–8 the most commonly detected genetic group was the 3C.2a cluster (43/58; 74.1%). Inside this cluster, the majority (34/43; 79.1%) of strains belonged to a single genetic 3C.2a subgroup 2 (3C.2a2), bearing antigenic substitutions T131K and R142K (site A) and R261Q (site E). The dominance of this 3C.2a2 in the 2017–8 inter-epidemic period in Brazil was similar to the 2017–8 season in Europe and Canada according their surveillance data. The new vaccine strain has five to six antigenic changes in comparison to the predominant 3C.2a2 circulating in South America since September 2017 until now. It is possible that the vaccine mismatch will not protect the population against a majority of circulating strains. Surveillance of the vaccine effectiveness supported by antigenic and serological analysis are necessary to prove this hypothesis. However, this highlights the difficulty of vaccine strain selection and highlights the need for of a universal influenza vaccine.
Collapse
Affiliation(s)
- P C Resende
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - B Caetano
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - A Matos
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - J Lopes
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - C Garcia
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - M Miranda
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - P Born
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - F C Motta
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - D Brown
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| | - M Siqueira
- Laboratory of Respiratory Viruses and Measles, National Influenza Centre, MoH and WHO – Oswaldo Cruz Institute – FIOCRUZ, Rio de Janeiro, Brazil
| |
Collapse
|
45
|
Genderini FG, Martiny D, Ponthieux F, Argudín MA, Gomez Galdon M, Zaarour A, Garcia C, Libois A, Gérard M, Dauby N. First case of Campylobacter rectus and Solobacterium moorei mixed bacteraemia successfully identified by MALDI TOF-MS. New Microbes New Infect 2019; 31:100587. [PMID: 31372234 PMCID: PMC6658993 DOI: 10.1016/j.nmni.2019.100587] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 06/21/2019] [Accepted: 06/26/2019] [Indexed: 11/07/2022] Open
Abstract
Campylobacter rectus and Solobacterium moorei are anaerobic Gram-negative and Gram-positive rods, respectively, that are occasionally members of the human oral flora. Bacteraemia has rarely been reported. We present the first case of mixed C. rectus–S. moorei bacteraemia in an individual with diabetes and human immunodeficiency virus infection. Both bacteria were successfully identified by MALDI-TOF MS.
Collapse
Affiliation(s)
- F G Genderini
- Infectious Diseases Department, Centre Hospitalier Universitaire (CHU) Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Infectious Diseases, Department of Mental and Physical Health and Preventive Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy
| | - D Martiny
- National Reference Centre for Campylobacter, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Faculté de Médecine et Pharmacie, Université de Mons, Mons, Belgium
| | - F Ponthieux
- Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - M A Argudín
- Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - M Gomez Galdon
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - A Zaarour
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CHU Saint-Pierre, Brussels, Belgium
| | - C Garcia
- Nuclear Medicine Department, Université Libre de Bruxelles (ULB), CHU Saint-Pierre, Brussels, Belgium
| | - A Libois
- Infectious Diseases Department, Centre Hospitalier Universitaire (CHU) Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - M Gérard
- Infectious Diseases Department, Centre Hospitalier Universitaire (CHU) Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - N Dauby
- Infectious Diseases Department, Centre Hospitalier Universitaire (CHU) Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
| |
Collapse
|
46
|
Garcia C, Soriano JM, Cortes V, Sevilla-Navarro S, Marin C, Catala-Gregori P. The use of dynamic prevalence maps to assess the prevalence of Salmonella in broiler flocks in the Valencian Community, Spain. REV SCI TECH OIE 2019; 37:1013-1020. [PMID: 30964452 DOI: 10.20506/rst.37.3.2903] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The aim of this study was to design and implement a dynamic prevalence map for managing the data collected within the framework of the Salmonella spp. National control plan in broiler flocks, using a data set from the Valencian Community, Spain. Such a map would be a useful tool for veterinarians seeking to define control options. The development of the mapping tool for this study involved three main phases: data collection, data analysis and data representation. The data used were obtained from the results of the National Control Programme (based on European Commission [EC] Regulation No. 2160/2003). The Salmonella prevalence data were represented on a map of the Valencian Community, which included geographical information on flock locations to facilitate the interpretation of the results from monitoring. The average prevalence of Salmonella spp. was 2.74% from 2009 to 2013. Moreover, the proportion of broiler flocks that remained positive for the target serovars according to EC Regulation No. 2160/2003 (S. Enteritidis and/orS. Typhimurium [including monophasic S. Typhimurium]) was less than 1%. Over the five-year period of the study (2009-2013), the area of Bajo Maestrazgo had the highest level of Salmonella spp. prevalence every year, thereby validating the usefulness of this mapping tool. The aim of the study is to detect geographical 'highpressure' Salmonella zones over time and make suggestions on where efforts should be focused in this region to reduce future Salmonella spp. prevalence. Local Veterinary Services could, using the map, identify the infection pressure of Salmonella in the geographical areas where farms are located. Proximity to higher prevalences may imply an increased risk of flock contamination. Although annual data are represented, data can be presented in real time with regular frequency (daily, weekly, monthly or quarterly) or even over periods of several years. Therefore, the dynamic prevalence map provides extremely useful epidemiological information to veterinarians on the prevention of Salmonella.
Collapse
|
47
|
Rigueiro A, Silvestre A, Squizatti M, Garcia C, Estevam D, Dias E, Felizari L, Demartini B, Caixeta E, Santi P, Arrigoni M, Millen D. 88 Feedlot performance and carcass traits of Nellore cattle fed virginiamycin to shorten the adaptation period to high-concentrate diets. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Rigueiro
- São Paulo State University (UNESP), School of Veterinary Medicine and Animal Science,Botucatu, São Paulo,Brazil
| | - A Silvestre
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, Sao Paulo, Brazil
| | - M Squizatti
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - C Garcia
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - D Estevam
- São Paulo State University (UNESP), School of Veterinary Medicine and Animal Science,Botucatu, São Paulo,Brazil
| | - E Dias
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - L Felizari
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - B Demartini
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - E Caixeta
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - P Santi
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| | - M Arrigoni
- São Paulo State University (UNESP), School of Veterinary Medicine and Animal Science,Botucatu, São Paulo,Brazil
| | - D Millen
- Sāo Paulo State University (UNESP), Animal Science College,Dracena, São Paulo, Brazil 17900-000, Sao Paulo, Brazil
| |
Collapse
|
48
|
Levy EB, Peer C, Sissung TM, Venkatesan A, Pandalai P, Greten T, Hughes MS, Garcia C, Peretti J, Figg W, Lewis A, Wood B. Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. J Vasc Interv Radiol 2018; 30:19-22. [PMID: 30527657 DOI: 10.1016/j.jvir.2018.06.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 06/22/2018] [Accepted: 06/28/2018] [Indexed: 12/12/2022] Open
Abstract
Differences in drug metabolism associated with UGT1A1 polymorphism could result in individualized local response to hepatic chemoembolization with irinotecan-eluting beads (DEBIRI) or predictable toxicities. Five patients with inoperable hepatic metastases from colorectal or anal malignancies treated with DEBIRI were assessed for UGT1A1 mutations. No difference in area under the curve (AUC) for SN38 in normal liver and tumor tissue samples was noted with variant or wild-type UBT1A1 (P = .16 and P = .05, respectively). Plasma SN-38 AUC was significantly lower in wild-type compared to variant patients (P < .0001). UGT1A1 genotype may not be predictive of hematologic toxicity after DEBIRI.
Collapse
Affiliation(s)
- Elliot B Levy
- Center for Interventional Oncology, Radiology and Imaging Sciences, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892.
| | - Cody Peer
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - Tristan M Sissung
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - Aradhana Venkatesan
- Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Austin, Texas
| | - Prakash Pandalai
- Kaiser Permanente, Mid-Atlantic Permanente Medical Group, Bethesda, Maryland
| | - Tim Greten
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - Marybeth S Hughes
- Department of Surgical Oncology, Eastern Virginia Medical School, Norfolk, Virginia
| | - Charisse Garcia
- Center for Interventional Oncology, Radiology and Imaging Sciences, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - Julie Peretti
- Center for Interventional Oncology, Radiology and Imaging Sciences, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - William Figg
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| | - Andrew Lewis
- Biocompatibles, UK Ltd, A BTG International Group Company, Conshohocken, Pennsylvania
| | - Bradford Wood
- Center for Interventional Oncology, Radiology and Imaging Sciences, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 1C367, Bethesda, MD 20892
| |
Collapse
|
49
|
Obed M, Garcia C, Palaoro A, Romandetta A, Alzogaray M, Mykietiuk A. Broad spectrum antibiotic prescription patterns in a tertiary private hospital in Argentina. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
50
|
Loureiro C, Garcia C, Adana L, Yacelga T, Rodriguez-Lorenzana A, Maruta C. [Use of the Montreal Cognitive Assessment (MoCA) in Latin America: a systematic review]. Rev Neurol 2018; 66:397-408. [PMID: 29897607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
AIM To analyze the frequency of use of the Montreal Cognitive Assessment (MoCA) as a cognitive screening instrument, cross-cultural adaptation, the existence of normative data and clinical validation studies in Latin America Hispanic countries. SUBJECTS AND METHODS The Medline, PsycINFO, Web of Science, Scopus and Scielo databases were consulted between April and June 2017 according to the PRISMA methodology. We included all studies referencing the MoCA as an instrument to evaluate cognitive deterioration conducted in Latin America and that included normative and psychometric data, as well as its clinical validation. RESULTS Of the 80 studies identified, 19 met the inclusion criteria. Most of the studies mentioned the use of the Spanish version of the MoCA and reported a statistically significant effect of gender, age and, most of all, education on the performance of this test. Only five studies presented with a detailed analysis of the psychometric characteristics of the test, and in most articles cut-off scores for the diagnosis of cognitive impairment were the same as the original study. CONCLUSIONS The small number of articles identified may reflect a late start of the use of MoCA in Latin America. A tendency towards the use of this test without making a cross-cultural adaptation and the use of international norms was observed in this region. The present systematic review demonstrates the need for future research tackling the development of a linguistically adapted version of the MoCA to Latin America and the study of its psychometric properties, with the aim of improving cognitive assessment.
Collapse
Affiliation(s)
- C Loureiro
- Universidad de las Americas, Quito, Ecuador
| | - C Garcia
- Universidad de las Americas, Quito, Ecuador
| | - L Adana
- Universidad de las Americas, Quito, Ecuador
| | - T Yacelga
- Universidad de las Americas, Quito, Ecuador
| | | | - C Maruta
- Laboratorio de Estudios de Lenguaje, Facultad de Medicina, Universidad de Lisboa, Lisboa, Portugal
| |
Collapse
|